English
manifaxine
Sign in to saveAlso known as GW-320,659
Manifaxine (developmental code name GW-320,659) is a norepinephrine–dopamine reuptake inhibitor developed by GlaxoSmithKline through structural modification of radafaxine, an isomer of hydroxybupropion and one of the active metabolites of bupropion. Manifaxine was researched for treatment of attention deficit hyperactivity disorder (ADHD) and obesity and was found to be safe, reasonably effective, and well-tolerated for both applications. However, no results were reported following these initial trials and development was discontinued.
Wikidata facts
- Developer
- GSK
- Mass
- 243.107
Show 5 more facts
- chemical formula
- C₁₂H₁₅F₂NO₂
- canonical SMILES
- CC1COC(C(N1)C)(C2=CC(=CC(=C2)F)F)O
- isomeric SMILES
- C[C@@H]1CO[C@]([C@@H](N1)C)(C2=CC(=CC(=C2)F)F)O
- subject has role
- norepinephrine-dopamine reuptake inhibitor
- Commons category
- Manifaxine
via Wikidata · CC0
~1 min read
Encyclopedic overview
3 sectionsContents
- Synthesis
- See also
- References
Manifaxine (developmental code name GW-320,659) is a norepinephrine–dopamine reuptake inhibitor developed by GlaxoSmithKline through structural modification of radafaxine, an isomer of hydroxybupropion and one of the active metabolites of bupropion. Manifaxine was researched for treatment of attention deficit hyperactivity disorder (ADHD) and obesity and was found to be safe, reasonably effective, and well-tolerated for both applications. However, no results were reported following these initial trials and development was discontinued.
==Synthesis== class=skin-invert-image|thumb|center|500px|Synthesis: Patent: See also:
Excerpted from Wikipedia’s “manifaxine” article, available under the CC BY-SA 4.0 licence.